The insider selling is routine and tax/liquidity-driven, not a bearish signal. With 90% analyst bullishness and a $2.4B market cap, the fundamental story (pipeline catalyst) remains intact. Monitor for any upcoming clinical data readout or regulatory update that could be a near-term catalyst.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 2 $33.86entry
- T+1 · 4mo ago −1.89%α −2.76% · $33.22
- T+5 · 4mo ago +6.20%α +5.27% · $35.96
- T+20 · 4mo ago +0.06%α +0.47% · $33.88
- T+60 · 7w ago −2.57%α −5.58% · $32.99
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three Pharvaris insiders, the Chief Medical Officer, Chief Early Development Officer, and a Director, sold a total of ~$665K in open-market shares over a 5-day window. The sales are small relative to the $2.4B market cap (~0.03%) and are largely tied to option exercises, suggesting routine tax- and liquidity-driven selling rather than a bearish signal. The cluster is not material enough to change the fundamental outlook for the stock.
Key Financial Metrics
Key Facts
- Three insiders sold a total of ~$665K in open-market shares over June 25-29, 2026.
- Chief Medical Officer Lu Peng sold ~$500K (largest sale), Chief Early Development Lesage Anne sold ~$81K, Director Schikan sold ~$84K.
- All open-market sales were preceded by option exercises at $0 or $2.59 strike, indicating tax-covering and liquidity-driven selling.
- Total open-market sales of ~$665K represent ~0.03% of Pharvaris' $2.4B market cap, well below the 0.1% materiality threshold.
- The cluster is 100% sell-side with no open-market purchases, but the dollar amounts are trivial relative to company size.
Financial Impact
Total open-market sales of ~$665K represent ~0.03% of Pharvaris' $2.4B market cap, immaterial.
Risk Factors
- Insider selling could accelerate if the stock continues to appreciate, but current levels are immaterial.
- Clinical-stage biotech risk: any negative pipeline data would outweigh insider activity entirely.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PHVS-1782946988269 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers